116283/Boehringer Ingelheim[Grants and Funding] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Effectiveness and safety of empagliflozin: final results from the EMPRISE study.

Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Déruaz-Luyet A, Paik JM, Patorno E. Htoo PT, et al. Diabetologia. 2024 Jul;67(7):1328-1342. doi: 10.1007/s00125-024-06126-3. Epub 2024 Mar 21. Diabetologia. 2024. PMID: 38509341

Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.

Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Déruaz-Luyet A, Paik JM, Patorno E. Htoo PT, et al. Cardiovasc Diabetol. 2024 Feb 8;23(1):57. doi: 10.1186/s12933-024-02150-0. Cardiovasc Diabetol. 2024. PMID: 38331813 Free PMC article.

Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study.

Tesfaye H, Wang KM, Zabotka LE, Wexler DJ, Schmedt N, Koeneman L, Seman L, Paik JM, Patorno E. Tesfaye H, et al. J Gen Intern Med. 2024 Aug;39(10):1870-1879. doi: 10.1007/s11606-024-08793-9. Epub 2024 May 6. J Gen Intern Med. 2024. PMID: 38710868

Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes.

Htoo PT, NajafZadeh M, Tesfaye H, Schneeweiss S, Wexler DJ, Glynn RJ, Schmedt N, Déruaz-Luyet A, Koeneman L, Paik JM, Patorno E. Htoo PT, et al. Diabetes Care. 2024 Nov 1;47(11):1900-1907. doi: 10.2337/dc24-0270. Diabetes Care. 2024. PMID: 38917305

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4 results

Search Page

Filters